High-density lipoprotein associations with coronary heart disease: Does measurement of cholesterol content give the best result?

Journal of Clinical Lipidology

Volumn 1, Issue 1, 2007, Pages 57-64

  Cromwell, William C ^a  

^a Presbyterian Center for Preventive Cardiology   (United States)

Author keywords

A I; Apolipoprotein; Coronary heart disease; HDL; HDL subclass; HDL P; Lipoprotein

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO;

ARTERY DISEASE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY RISK; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PREDICTION; PRIORITY JOURNAL; RESTENOSIS; STROKE; SUDDEN DEATH;

EID: 34248206764     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.01.002     Document Type: Article

References (57)

1. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 361 (2003) 777-780
2. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Int Med 259 (2006) 247-258
3. Gotto A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., and Weis S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
4. Simes R.J., Marschner I.C., Hunt D., Colquhoun D., Sullivan D., and Stewart R.A.H. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in the ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 105 (2002) 1162-1169
5. van Lennep J.E., Westerveld H.T., van Lennep H.W., Zwinderman A.H., Erkelens D.W., and van der Wall E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 20 (2000) 2408-2413
6. Otvos J.D., Jeyarajah E.J., and Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90 suppl (2002) 22i-29i
7. Otvos J.D. Why cholesterol measurements may be misleading about lipoprotein levels and cardiovascular disease risk-clinical implications of lipoprotein quantification using NMR spectroscopy. J Lab Med 26 (2002) 544-550
8. Cromwell W.C., and Otvos J.D. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6 (2004) 381-387
9. Toth P.P. High-density lipoprotein and cardiovascular disease. Circulation 09 (2004) 1809-1812
10. Brown B.G., Stukovsky K.H., and Zhao X.Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 17 (2006) 631-636
11. Rye K.A., and Barter P.J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 24 (2004) 421-428
12. Assmann G., and Nofer J.R. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 54 (2003) 321-341
13. Navab M., Ananthramaiah G.M., Reddy S.T., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45 (2004) 993-1007
14. Sniderman A.D., Acantlebury T., and Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Int Med 135 (2001) 447-459
15. Garvey W.T., Kwon S., Zheng D., et al. The effects of insulin resistance and type 2 diabetes mellitus on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-462
16. Goff D.C., D'Agostino Jr. R.B., Haffner S.M., and Otvos J.D. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 54 (2005) 264-270
17. Festa A., Williams K., Hanley A.J.G., et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 111 (2005) 3465-3472
18. Rader D.J., Hoeg J.M., and Brewer Jr. H.B. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 120 (1994) 1012-1025
19. Thompson A., and Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ration and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 259 (2006) 481-492
20. Wald N.J., Law M., Watt H.C., et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 343 (1994) 75-79
21. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104 (2001) 1108-1113
22. Sweetnam P.M., Bolton C.H., Downs L.G., et al. Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest 30 (2000) 947-956
23. Simons L.A., Simons J., Friedlander Y., and McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 159 (2001) 201-208
24. Luc G., Bard J.M., Ferrieres J., et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 22 (2002) 1155-1161
25. Kontush A., and Chapman M.J. Antiatherogenic small, dense HDL-guardian angel of the arterial wall?. Nat Clin Pract Cardiovasc Med 3 (2006) 144-153
26. Parra H.J., Arveiler D., Evans A.E., et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM Study. Arterioscler Thromb 12 (1992) 701-707
27. Puchois P., Kandoussi A., Fievet P., et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 68 (1987) 35-40
28. Coste Burel M., Mainard F., Chivot L., Auget J.L., and Madec Y. Study of lipoprotein particles LpAI and LpAI:AII in patients before coronary bypass surgery. Clin Chem 36 (1990) 1889-1891
29. Genest Jr. J.J., Bard J.M., Fruchart J.C., Ordovas J.M., Wilson P.F., and Schaefer E.J. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis 90 (1991) 149-157
30. Syvanne M., Kahri J., Virtanen K.S., and Taskinen M.R. HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation 92 (1995) 364-370
31. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., and Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325 (1991) 373-381
32. Miller N.E. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 113 2 Pt 2 (1987) 589-597
33. Johansson J., Carlson L.A., Landou C., and Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 11 (1991) 174-182
34. Silverman D.I., Ginsburg G.S., and Pasternak R.C. High-density lipoprotein subfractions. Am J Med 94 (1993) 636-645
35. Gofman J.W., Young W., and Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation 34 (1966) 679-697
36. Cheung M.C., Brown B.G., Wolf A.C., and Albers J.J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 32 (1991) 383-394
37. Salonen J.T., Salonen R., Seppanen K., Rauramaa R., and Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 84 (1991) 129-139
38. Lamarche B., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., and Despres J.P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 17 (1997) 1098-1105
39. Hattori H., Kujiraoka T., Egashira T., et al. Association of coronary heart disease with pre-beta-HDL concentrations in Japanese men. Clin Chem 50 (2004) 589-595
40. Yu S., Yarnell J.W., Sweetnam P., and Bolton C.H. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis 166 (2003) 331-338
41. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
42. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
43. Asztalos B.F., Batista M., Horvath K.V., et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 23 (2003) 847-852
44. Ruotolo G., Ericsson C.-G., Tettamanti C., et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 32 (1998) 1648-1656
45. Syvänne M., Nieminen M.S., Frick M.H., et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 98 (1998) 1993-1999
46. Jeyarajah E.J., Cromwell W.C., and Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26 (2006) 847-870
47. Mora S., Szklo M., Otvos J.D., et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis (2006) [Epub ahead of print]
48. Rosenson R.S., Freedman D.S., and Otvos J.D. Relations of lipoprotein subclass levels and LDL size to progression of coronary artery disease in the PLAC I trial. Am J Cardiol 90 (2002) 89-94
49. Kuller L., Arnold A., Tracy R., et al. NMR spectroscopy of lipoproteins and risk of CHD in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 22 (2002) 1175-1180
50. Freedman D.S., Otvos J.D., Jeyarajah E.J., Barboriak J.J., Anderson A.J., and Walker J. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 18 (1998) 1046-1053
51. Soedamah-Muthu S.S., Chang Y.-F., Otvos J., Evans R.W., and Orchard T.J. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 46 (2003) 674-682
52. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
53. Mänttäri M., Koskinen P., Manninen V., Huttunen J.K., Frick M.H., and Nikkilä E.A. Effect of gemfibrozil on the concentration and composition of serum lipoproteins. Atherosclerosis 81 (1990) 11-17
54. Guerin M., Le Goff W., Frisdal E., et al. Action of ciprofibrate in Type IIB hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 88 (2003) 3738-3746
55. Freedman D.S., Otvos J.D., Jeyarajah E.J., et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: The Framingham Study. Clin Chem 50 (2004) 1189-1200
56. Cromwell WC, Otvos JD. Clinical utilization of lipoprotein subfractions. In: Davidson MH, Toth PP, Maki K, eds. Therapeutic Lipidology. Totawa, NJ: Humana Press. In press.
57. Brewer H.B., Remaley A.T., Neufeld E.B., Baso F., and Joyce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 24 (2004) 1755-1760